Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The REBOOT-PARADOX trial evaluated TAVR plus medical therapy versus medical treatment alone in symptomatic paradoxical low-flow, low-gradient aortic stenosis, showing no definitive mortality benefit but supporting personalized care with tim
This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR’s durable benefit.
The 3-year results of the LYTEN trial demonstrate that self-expanding valves provide significantly better hemodynamic performance than balloon-expandable valves for failed small surgical bioprostheses, although clinical outcomes like mortal
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id